A Home Blood Pressure Monitoring Study Comparing the Antihypertensive Efficacy of Two Angiotensin II Receptor Antagonist Fixed Combinations

The superior BP-lowering potency of the fixed combination irbesartan/HCTZ (150/12.5 mg) over valsartan/HCTZ (80/12.5 mg), evidenced independently from the investigators by HBPM, supports the use of this technique in trials with prospective, randomized, open-label, blinded-endpoint designs.